NEWS

InnoStudio will launch their samples of remdesivir-SBECD to the International Space Station (ISS), using the commercial service "Kirara" provided by Japan Manned Space Systems Corporation (JAMSS), which is to be launched in December 2020 (Kirara#2). This is the first space experiment for COVID-19 drug discovery research in the world by the investigation of JAMSS and InnoStudio.

<Related Articles>
JAMSS supports COVID-19 space research consortium
FIRST EXPERIMENTS IN SPACE FOR COVID-19 DRUG RESEARCH

<About Kirara>
Kirara is a high-quality protein crystal growth service provided by JAMSS for drug discovery support. This technology was realized through a technical tie-up with Confocal Science, which has been supporting protein crystal generation on ground and in space since its foundation in 1994. The small incubator, which JAMSS developed and in which crystals are grown, is launched through the ICE Cubes Service and accommodated in the ICE Cubes Facility (ICF) owned by Space Applications Services who has a commercial partnership with the European Space Agency (ESA). Kirara is a commercial service partnership between Japanese and European companies. It could be applied to the field of materials such as cellulose as well as drug discovery support.
Kirara service

<businesswire URL>
https://www.businesswire.com/news/home/20201130005370/en/